Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Summit Therapeutics (SMMT) over the last 10 years, with Q3 2025 value amounting to $238.6 million.

  • Summit Therapeutics' Cash & Equivalents rose 15438.98% to $238.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $238.6 million, marking a year-over-year increase of 15438.98%. This contributed to the annual value of $104.9 million for FY2024, which is 4681.41% up from last year.
  • As of Q3 2025, Summit Therapeutics' Cash & Equivalents stood at $238.6 million, which was up 15438.98% from $297.9 million recorded in Q2 2025.
  • In the past 5 years, Summit Therapeutics' Cash & Equivalents ranged from a high of $348.6 million in Q4 2022 and a low of $23.8 million during Q3 2023
  • Its 5-year average for Cash & Equivalents is $124.5 million, with a median of $98.0 million in 2021.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first plummeted by 8049.37% in 2023, then surged by 94759.09% in 2025.
  • Over the past 5 years, Summit Therapeutics' Cash & Equivalents (Quarter) stood at $71.8 million in 2021, then skyrocketed by 385.59% to $348.6 million in 2022, then crashed by 79.51% to $71.4 million in 2023, then soared by 46.81% to $104.9 million in 2024, then skyrocketed by 127.49% to $238.6 million in 2025.
  • Its Cash & Equivalents stands at $238.6 million for Q3 2025, versus $297.9 million for Q2 2025 and $211.5 million for Q1 2025.